COVID-19 ARDS patients had significantly higher plasma concentrations of CCL5 (p = 0.025) and non-significantly higher plasma concentrations of CXCL2 (p = 0.094), CXCL10 (p = 0.287), CD40 ligand (p = 0.125), IL-10 (p = 0.232), and GM-CSF (p = 0.332) compared with non-COVID-19 ARDS patients. This evidence concerns the gene CXCL2 and COVID-19.